Journals / Türk Klinik Biyokimya Dergisi / 2020 / Cilt: 18 - Sayı: 2

Osteopontin Levels in Ocular Behçet's disease: A Controlled Study

Göz Tutulumu Olan Behçet Hastalığında Osteopontin Düzeyleri: Kontrollü Çalışma

Pages
77–84
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This may suggest that OPN might not be an important cytokine at least in BD eye disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Osteopontin (OPN) is a cytokine involved in inflammatory and autoimmune mechanisms.
📊
Key Findings & Data:Materials and methods: OPN, interleukin-10 (IL-10) and interleukin-12 (IL-12) levels were measured in 22 BD patients (once during an eye attack and once when the attack subsided) as well as 18 SLE patients and 18 healthy controls.
💡
Conclusion & Impact:This may suggest that OPN might not be an important cytokine at least in BD eye disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Osteopontin (OPN) is a cytokine involved in inflammatory and autoimmune mechanisms. In this study, we aimed to investigate OPN role in eye involvement in Behçet's disease (BD). To assess OPN in eye involvement in BD by comparing OPN and other cytokine levels both in BD and in systemic lupus erythematous (SLE), an autoimmune disease, and in healthy controls. Materials and methods: OPN, interleukin-10 (IL-10) and interleukin-12 (IL-12) levels were measured in 22 BD patients (once during an eye attack and once when the attack subsided) as well as 18 SLE patients and 18 healthy controls. Results: The OPN levels were increased in SLE and in active and inactive Behçet's uveitis. The IL-10 and IL-12 were significantly increased only in SLE patients. Conclusions: Although OPN levels in BD patients were significantly higher with healthy controls, no differences in OPN levels were observed between active-inactive Behçet's uveitis or between active Behçet's uveitis and SLE. This may suggest that OPN might not be an important cytokine at least in BD eye disease.

Özet

Amaç: Osteopontin (OPN), inflamatuvar ve otoimmün mekanizmalarla ilgisi bulunan bir sitokindir. Bu çalışmada, göz tutulumu olan Behçet hastalarında OPN’in rolünü değerlendirmek amaçlanmıştır. Göz tutulumu olan Behçet hastalarındaki OPN, İnterlökin-10 (IL-10) ve İnterlökin-12 (IL-12) düzeyleri, bir otoimmün hastalık olan sistemik lupus eritematozus (SLE) ve sağlıklı kontrol gruplarıyla kıyaslanmıştır. Gereç ve Yöntem: OPN, IL-10 ve IL-12 düzeyleri, göz tutulumu olan 22 Behçet hastasında (önce üveit atağı sırasında, sonra remisyona girdiğinde olmak üzere iki defa), 18 SLE hastasında ve 18 sağlıklı bireyde ölçülmüştür. Bulgular: OPN düzeyleri aktif ve inaktif üveyitli gruptaki Behçet ve SLE hasta gruplarında artmıştır. IL10 ve IL-12 düzeyleri yalnızca SLE hasta grubunda anlamlı artış göstermiştir. Sonuç: OPN düzeyleri sağlıklı kontrollere kıyasla Behçet hastalarında artmış olsa da, aktif ve inaktif üveyit dönemleri arasında anlamlı bir fark oluşturmamıştır. Aynı şekilde aktif üveyit dönemindeki Behçet hastaları ile SLE hastaları arasında da anlamlı bir fark bulunmamıştır. Böylece, Behçet hastalığının en azından göz tutulumunda, OPN’in önemli bir sitokin olmayabileceği öne sürülebilir.

🔖

Cite This Article

TUZCU, A., UĞURLU, S., ANDICAN, G., ÖZYAZGAN, Y., YAZICI, H. (2022). Osteopontin Levels in Ocular Behçet's disease: A Controlled Study. Türk Klinik Biyokimya Dergisi, Cilt: 18 - Sayı: 2, 77–84. https://ajindex.com/articles/634328

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Yazici Y, Yurdakul S, et al. Behçet’s Syndrome. CurrRheumatol Rep. 2010
  2. 12(6): 429-35. 2. Onder M, Gurer MA. The multiple faces of Behcet’s disease and its aetiological factors. J Eur Acad Dermatol Venereal. 2001
  3. Evereklioğlu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005
  4. Doğanavşargil E, Keser G. BehçetHastalığı. T Klin J Int Med Sci. 2005
  5. Hamzaoui K, Hamzaoui A, et al. Cytokine profile in Behçet's disease patients. Scand J Rheumatol. 2002
  6. Ilhan F, Demir T, et al. Th1 polarization of the immune response in uveitis in Behçet's disease. Can J Ophthalmol. 2008
  7. Yasuı T, Sato M, et al. Effects of citrate on renal stone formation and osteopontin in a rat urolithiasis model. Urol Res. 2001
  8. Sodek J, Ganss B, et al. Osteopontin. Crit Rev Oral Biol. Med. 2000
  9. Mazalli M, Kipari T, et al. Osteopontin--a molecule for all seasons. Q J Med. 2002
  10. Wang KX, Denhardt DT. Osteopontin: Role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008
  11. Heilmann K, Hoffmann U, et al. Osteopontin as a two-sided mediator of intestinal inflammation. J Cell Mol Med. 2009
  12. Zheng Y, Wang Z, Deng L, et al. Osteopontin promotes inflammation in patients with acute coronary syndrome through its activity on IL-17 producing cells. EurJ Immunol. 2012
  13. 42(10): 2803- 14. 13. Angrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005
  14. 201(2): 233–40. 14. Chi W, Zhu X, Yang P, et al.Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008
  15. 49(7): 3058-64. 15. Yamamoto N, Nakashima T, et al. Successful treatment of collagen-induced arthritis in nonhuman primates by chimeric anti-osteopontin antibody. IntImmunopharmacol. 2007
  16. Kaleta B. Role of Osteopontin in Systemic Lupus Erythematosus. Arch. Immunol. Ther. Exp. 2014
  17. 62(6): 475-82. 17. Kitamura M, Iwabuchi K, et al. Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J Immunol. 2007
  18. Morimoto J, Kon S, et al. Osteopontin
  19. as a target molecule for the treatment of inflammatory diseases. Targets. 2010
  20. Iwata D, Kitamura M, et al. Prevention of experimental autoimmune uveoretinitis by blockade of osteopontin with small interfering RNA. Exp Ey